New ALS Drug Will Be Priced at $158,000 a Year




  • In Business
  • 2022-09-30 23:12:07Z
  • By The Fiscal Times
 

The Food and Drug Administration on Thursday approved a new medication for Amyotrophic Lateral Sclerosis (A.L.S), the debilitating and deadly neurological disorder also known as Lou Gehrig's Disease. On Friday, the drug's manufacturer, Amylyx Pharmaceuticals, announced the list price of the drug will be $158,000.

That list price, Pam Belluck of The New York Times notes, is far higher than the annual price of $9,100 to $30,700 recommended by the Institute for Clinical and Economic Review, a nonprofit that evaluates the value of drugs.

"Amylyx officials predicted that most patients would pay little or nothing for the treatment because the company expects insurers, both private and public, to cover it. Amylyx plans to provide it free to uninsured patients experiencing financial hardship," Belluck reports.

She adds that the new drug, to be marketed under the name Relyvrio, was approved by the FDA "even though the agency's analysis concluded there was not yet sufficient evidence that the medication could help patients live longer or slow the rate at which they lose functions like muscle control, speaking or breathing without assistance."

The agency said the approval was merited even without additional evidence of the drug's effectiveness because the medication is considered safe and "given the serious and life-threatening nature of A.L.S. and the substantial unmet need, this level of uncertainty is acceptable in this instance."

Amylyx says that there are about 29,000 people living with A.L.S. in the United States and at least 200,000 people with the disease worldwide.

On a related note, the Office of Inspector General at the Department of Health and Human Services said this week that the F.D.A.'s accelerated approval process for drugs raised some concerns.

In a study of the agency's accelerated approvals, the HHS watchdog found that 34% have at least one confirmatory trial past its planned completion date and four of the 278 drugs granted accelerated approval are five years or more past their original completion dates.

"The accelerated approval pathway holds promise for patients who face serious illnesses where adequate treatments are lacking," the watchdog report said. "However, for a variety of reasons, sponsors do not always complete trials promptly. This can result in drugs staying on the market-and being administered to patients-for years without the predicted clinical benefit being verified. And insurers-including Medicare and Medicaid-paying billions for treatments that are not verified to have clinical benefit."

The Office of Inspector General estimated that Medicare and Medicaid spent more than $18 billion from 2018 to 2021 on drugs that had been granted accelerated approval but still had incomplete confirmatory trials past their original completion dates.

Read more about the F.D.A approval process at Kaiser Health News.

Like what you're reading? Sign up for our free newsletter.

COMMENTS

More Related News

U.S. FDA declines to approve Y-mAbs
U.S. FDA declines to approve Y-mAbs's pediatric cancer drug

Y-mAbs said it is assessing the implications of the Food and Drug Administration's complete response letter (CRL) and the company's plans for the drug's development program. The FDA's decision follows a unanimous vote by its advisers in October against the drug, omburtamab, to treat neuroblastoma due to insufficient evidence that it improves overall survival. "We are disappointed but not surprised based on the outcome of the (FDA advisory panel) meeting," interim Chief Executive Officer Thomas Gad said in a statement.

U.S. FDA approves Rigel Pharma
U.S. FDA approves Rigel Pharma's treatment for a type of leukemia

The Food and Drug Administration approved the drug, which will be sold under the brand Rezlidhia, for the treatment of a type of cancer of the blood and bone marrow called acute myeloid leukemia in patients with a susceptible genetic mutation. Approval for the oral drug was supported by data from the company's mid-stage study, which showed a 35% rate for complete remission of the cancer with a complete or partial recovery in blood count. Rezlidhia will be the company's second treatment to get approval from the FDA after Tavalisse for a rare bleeding disorder called immune thrombocytopenic purpura.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Business